[Federal Register Volume 88, Number 95 (Wednesday, May 17, 2023)]
[Notices]
[Page 31511]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-10485]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by communicating with the Technology Transfer and Intellectual Property 
Office, National Institute of Allergy and Infectious Diseases, 5601 
Fishers Lane, Rockville, MD 20852 by contacting Dr. Benjamin Hurley at 
240-669-5092 or [email protected]. A signed Confidential 
Disclosure Agreement will be required to receive copies of unpublished 
information related to the invention.

SUPPLEMENTARY INFORMATION: Technology description follows:

Nanoparticle Vaccine Against Mpox

    Description of Technology:
    In 2022, the World Health Organization declared an atypical 
outbreak of monkeypox (Mpox), which has caused approximately 30,000 
cases of Mpox infection within the United States as of April 2023. Mpox 
represents a current threat to public health, and there is an immediate 
need for an effective vaccine. To address this, NIAID has developed a 
vaccine approach comprising virus-like nanoparticles coated with 
modified Mpox proteins. NIAID investigations have demonstrated that 
immunization has elicited a robust immune response in mice and provided 
protection against a lethal infection of Vaccinia virus.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:
     Immunization: Mpox nanoparticle vaccines may be more 
effective than current MVA vaccination approaches in providing 
protection against Mpox infection.
     The methodology for manufacturing the Mpox nanoparticle 
vaccine could be readily adapted to generate vaccines for other 
poxviruses.
    Competitive Advantages:
     A Mpox nanoparticle vaccine may have fewer side effects 
than available MVA based vaccines.
     The storage and transport requirements of a Mpox 
nanoparticle vaccine are better suited to low resource settings than 
MVA vaccines.
    Inventors: Bernard Moss, MD, Ph.D.
    Publications: Publication pending.
    Intellectual Property: HHS Reference No. E-183-2022; U.S. 
Provisional Application No. 63/402,702.
    Licensing Contact: To license this technology, please contact 
Benjamin Hurley at 240-669-5092 or [email protected], and 
reference E-183-2022.
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate, or commercialize this invention. For collaboration 
opportunities, please contact Benjamin Hurley; 240-669-5092, 
[email protected].

    Dated: May 9, 2023.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2023-10485 Filed 5-16-23; 8:45 am]
BILLING CODE 4140-01-P